| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.36 | 3e-23 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.48 | 4e-21 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.29 | 4e-14 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-11 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.33 | 4e-11 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.23 | 8e-10 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.33 | 3e-09 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.2 | 8e-09 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.32 | 8e-09 |